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Abstract 
Drug resistance of pathogens has necessitated the identification of novel targets for antibio-
tics. Thiamin (vitamin B1) is an essential cofactor for all organisms in its active form thiamin 
diphosphate (ThDP). Therefore, its metabolic pathways might be one largely untapped source 
of  antibiotics  targets.  This  review  describes  bacterial  thiamin  biosynthetic,  salvage,  and 
transport pathways. Essential thiamin synthetic enzymes such as Dxs and ThiE are proposed 
as promising drug targets. The regulation mechanism of thiamin biosynthesis by ThDP ri-
boswitch is also discussed. As drug targets of existing antimicrobial compound pyrithiamin, 
the ThDP riboswitch might serves as alternative targets for more antibiotics. 
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Introduction 
Inexorable increase of  drug  resistant pathogens 
has exacerbated the dire  outcome  of  recalcitrant  in-
fectious diseases due to limited effective antibiotics. A 
notorious case o f   p o i n t   i s   t h e   d r u g   r e s i s t a n c e   o f  My-
cobacterium tuberculosis, the causative agent of tuber-
culosis (TB). T B   i s   a  l e a d i n g   c a u s e   o f   d e a t h   w o r l d w i d e : 
about two million deaths and 9.4 million prevalent 
cases  (300,  000  multidrug  resistant  cases  included) 
were estimated in 2008 alone [World Health Organi-
zation, 2009]. To tackle infections diseases, especially 
the drug resistance infection, it is urgent to find novel 
antibiotics against unexplored drug targets. 
To maximally potential toxic and side-effect, an 
ideal antimicrobial compound should target pathogen 
u n i q u e   p a t h w a y s   o r   m o l e c u l e s .   Biosynthetic  path-
w a y s   o f   s e v e r a l   c ofactors have been proposed accor-
dingly as encouraging antibiotic targets such as the 
pantothenate  kinase  involving  i n   c o e n z y m e   A   b i o-
synthesis,  the  lumazine  synthase  (LS)  of  riboflavin 
biosynthesis,  and  the  NMN/NaMN  adenylytranfe-
rase  (NMNAT), NAD  synthetase  (NADS),  NAD  ki-
nase (NADK) involving in the NAD (P) biosynthesis 
pathway [1-3]. 
Thiamin (Vitamin B1) is indispensable for the ac-
tivity of the carbohydrate and branched-chain amino 
acid  metabolic  enzymes  in  its  active  form  thiamin 
diphosphate (ThDP). Therefore it is an  essential  co-
factor for all organisms [4-6].   M o s t   b a c t e r i a , as well as 
fungi and plants, could produce thiamin de novo, but 
m a m m a l s   d e p e n d   s o l e l y   o n   t h e   d i e t a r y   u p t a k e .   Re-
cently,  the  thiamin  metabolism pathway of Plasmo-
dium falciparum, the p a t h o g e n i c   a g e n t   o f   t r o p i c a l   m a-
laria, h a s   b e e n   s u g g e s t e d   a s   a   s o u r c e   o f   d r u g   t a r g e t s  
recently [7]. It is logical that the thiamin biosynthetic 
enzymes and underlying r e g u l a t i o n   n e t w o r k   m i g h t   b e  
suitable  drug  targets  for  the  development  of  novel 
antimicrobial agents.  
ThDP-dependent enzymes are crucial for 
pathogens 
ThDP-dependent  enzymes  such  as  pyruvate 
dehydrogenase (PDH), 2-oxoglutarate dehydrogenase Int. J. Biol. Sci. 2011, 7 
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(OGDH),  transketolase  (TK),  and  acetohydroxyacid 
synthase (AHAS), are involved in various enzymatic 
reactions  and  multiple  pathways. PDH  bridges  the 
glycolysis  and  the  citric  acid  cycle  via  acetyl-CoA. 
ODGH catalyzes a rate-limiting step of the citric acid 
cycle. TK plays a crucial role in the pentose phosphate 
pathway  and  AHAS  participates  in  the 
branched-chain  amino  acid  biosynthesis.  These 
ThDP-dependent  enzymes  are  essential  for  many 
crucial pathways and are conserved among pathogens 
including M. tuberculosis (Table 1). 
 
Table 1. The distribution of several ThDP-dependent enzymes in M. tuberculosis H37Rv. Abbreviations: AHAS, acetohy-
droxyacid synthase; DXS, 1-deoxy-D-xylulose-5-phosphate synthase; InPDC, indole-3-pyruvate decarboxylase; PDC, py-
ruvate decarboxylase; OGDH, 2-oxoglutarate dehydrogenase; PDH, pyruvate dehydrogenase; TK, transketolase. 
EC  Enzyme  ORF  Identity with hu-
man homology 
(amino acid)  
Pathway  Known inhibitors  References 
2.2.1.6  AHAS  Rv3003c 
Rv3509c 
N.A  Branched-chain 
amino acid biosyn-
thesis 
Metsulfuron-methyl, sulfonylureas, imidazo-
lines, pyrimidinythiobenzoates, phthalazin-1 
(2H) -one, KHG20612 
[8] [9, 10] 
4.1.1.47  Dxs  Rv2682c  N.A  Thiamin, nonmeva-
lonate and pyridoxal 
biosynthesis 
Bacimethrin, Clomazone,  
2-Methyl-3- (4-fluorophenyl) -5- 
(4-methoxy-phenyl) -4H- pyrazolo[1, 
5-a]pyrimidin-7-one, fluoropyruvate 
[11, 12] [13] 
4.1.1.74 
/4.1.1.1 
InPDC 
/PDC 
Rv0853c  24% (117/497)   Tryptophan catabol-
ism /Glycolysis 
N. A  N.A 
1.2.4.2  OGDH  N.A*  N.A  Citric acid cycle  3-Deaza ThDP, Bacimethrin  [11, 12, 14] 
1.2.4.1  PDH  Rv2497c,  
Rv2496c 
39% (139/358)   Pyruvate metabolism Acetylphosphinate, Thiamin thiazolone di-
phosphate (ThTDP), Thiamin thiothiazolone 
diphosphate (ThTTDP), Methylacetylphospho-
nate (PLThDP)  
[15-17] 
2.2.1.1  TK  Rv1449c  25% (162/650)   Pentose-phosphate 
pathway 
Oxythiamin, N3’-pyridyl thiamin, bacimethrin   [11, 12, 18, 19] 
N.A: Not applicable; *M. tuberculosis is identified to be lack of OGDH[90]. 
 
However,  few  ThDP-dependent  enzymes  are 
microbe  specific. Therefore, it is no  wonder  that  no 
clinical novel antibiotics emerged from their inhibi-
tors  were  reported  [20].  One  ThDP-dependent  en-
z y m e   r e c e n t l y   i n   t h e   s p o t l i g h t   i s   A H A S .   A H A S ,  a 
ThDP and FAD dependent enzyme, is involved in the 
synthesis of branched-chain amino acids (BCAAs) in 
plants, algae, fungi, bacteria, and archaea, but absent 
in animals. As the first common enzyme in the BCAA 
biosynthetic pathway,  AHAS is the potential targets 
for herbicides, fungicides,  and antimicrobial agents. 
In  fact,  many  AHAS  inhibitors,  such  as  metsulfu-
ron-methyl  (Figure  3a),  sulfonylureas  (Figure  3a), 
imidazolines,  pyrimidinythiobenzoates  and  phthala-
zin-1 (2H) -one, have been developed as herbicides 
[9].  Metsulfuron-methyl  can  inhibit  the  activity  of 
A H A S   b y   b i n d i n g   t h e   m o u t h   o f   t h e   a c t i v e   s i t e   a n d  
blocking its access to the ThDP [8]. Previous studies of 
amino acids auxotrophic strains of mycobacteria and 
the  AHAS  mutant  of  Burkholderia  pseudomallei  have 
s h o w n   t h a t   m i c r o b i a l   A H A S   m i g h t   b e   a   d r u g   t a r g e t  
against  infectious  disease  including  tuberculosis 
[21-23]. Herbicide sulfonylureas can  inhibit  the  My-
cobacterium avium AHAS [24]. Several efficient inhibi-
t o r s   a g a i n s t   A H A S   f r o m   M. tuberculosis (for  exmple, 
KHG20612, Figure  3a) and  Bacillus anthracis are do-
cumented [9, 10, 25, 26]. 
Other  ThDP-dependent  enzymes  shared  by 
bacteria  and  animals  still  deserves  considerable  at-
tention  since  there  might  be  huge  discrepancy  be-
tween microbial enzymes and human counterpart in 
the sequence and higher structures. TK  from  P. falci-
parum  has  been  reported  as  a  novel  target  to  treat 
malarial infection[27]. TK in human beings is also a 
promising  drug  target  for  the  treatment  of  cancer 
since the suppress activity of TK against tumor cell is 
much more profound than that against normal cells. 
Many  effective  TK  inhibitors  have  been  identified 
such  as  the  oxythiamin  and  N3’-pyridyl  thiamin 
(Figure  3a)  [18,  19].  3-deazathizmin  diphosphate 
(3-deaza ThDP) i s   o n e   o f   t h e   m o s t   p o t e n t   i r r e v e r s i b l e  
inhibitors  of  ThDP-dependent  enzymes.  The  only 
difference between this compound and ThDP is that 
the N-3   a t o m   o f   T h D P   h a s   b een replaced by a carbon 
atom resulting in the formation of a neutral thiophene 
ring in place of the thiazolium ring [14]. This neutral 
thiophene  ring  endows  3-d e a z a   T h D P   m o r e   h y d r o-
phobility than that of ThDP thereby stronger interac-
t i o n s   w i t h   t h e   a c t i v e   s i t e   o f   T h D P   d e p e n d e n t   e n z y m e s .  
In  fact, based on the enzymatic studies of  pyruvate 
decarboxylase from Zymomonas mobilis, 3-deaza ThDP 
binds this enzyme more rapidly and tightly compared 
with  ThDP,  ie,  with  a  rate  of  approximately  sev-
en-fold faster and 2, 5000 fold more tighter [14]. Sim-Int. J. Biol. Sci. 2011, 7 
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ilar results are also described in the binding with the 
E1 subunit of OGDH from E. coli, which  showed  a 
binding rate of 70-fold faster and 500-fold tighter than 
that of ThDP [14].  
Bacterial thiamin biosynthesis  
Prokaryotic  thiamin  biosynthesis  is  well- 
documented, which involves the formation of thiazole 
moiety  (4-methyl-5-β-hydroxyethyl  thiazole  phos-
p h a t e   o r   T H Z -P)  and  pyrimidine  moiety 
(4-amino-5-hydroxymethyl-2-methyl-pyrimidine  py-
rophosphate  or  HMP-PP)  separately  [5].  Thiamin 
biosynthetic  pathway  of facultative anaerobe E. coli 
and aerobe Bucillus subtilis are  the  two  best  studied 
examples (Figure 1). In E. coli, THZ-P is derived from 
an oxidative condensation of tyrosine,  cysteine, and 
1-deoxy-D-xylulose  5-phosphate (DXP). Seven genes 
(thiF, thiS, thiG, thiH, thiI, iscS, and Dxs) are involved 
i n   t h i s   p r o c e s s  [28-35]. B. subtilis THZ-P biosynthesis is 
different from E. coli since thiazole synthase (ThiH) is 
r e p l a c e d   b y   g l y c i n e   o x i d a s e  (ThiO) [36], which utilizes 
glycine instead of tyrosine to form dehydroglycine to 
provide the C2-N3 unit for THZ-P.  
The HMP-PP is produced from aminoimidazole 
ribotide (AIR) [28], a n   i n t e r m e d i a t e   o f   p u r i n e   b i o s y n-
thesis pathway. Hydroxymethyl pyrimidine synthase 
(ThiC) catalyzes  AIR  to  form  hydroxymethl pyrimi-
dine phosphate (HMP-P),  which is then phosphory-
lated  to  HMP-PP  by  Hydroxymethyl  pyrimidine 
(phosphate) kinase (ThiD). THZ-P  and  HMP-PP  are 
coupled  to  form  thiamin  monophosphate  (ThMP) 
mediated by thiamin phosphate synthase (ThiE), and 
thiamin  phosphate  kinase  (ThiL)  catalyze  a  final 
phosphorylation step to yield ThDP,  the active  form 
of thiamin. 
Thiamin salvage and transport pathways 
In most microorganisms, thiamin or its compo-
nents THZ-P and HMP-PP, could all be produced via 
salvage  pathway  (Figure  2)  [38].  Thiazole  alcohol 
(THZ) c a n   b e   u s e d   t o   f o r m   T H Z -P catalyzed by thia-
zole kinase (ThiM). ThiD is required for the salvage of 
HMP-PP  from  pyrimidine  alcohol  (HMP),  while 
thiamin  in  bacteria  can  be  converted  to  ThMP  by 
thiamin kinase (ThiK) in E. coli or to ThDP by thiamin 
pyrophosphokinase (ThiN) in B. subtilis. 
Exogenous thiamin and its components, ThiMP, 
ThDP, HMP, THZ, could also enter the cell via trans-
porters (Figure 2) [39-41]. Some gram-negative bacte-
ria, such as, E .   c o l i  and Salmonella typhimurium, contain 
an ATP-binding cassette (ABC ) transporter encoded 
by thiamin-regulated  operon, w h i c h   c o m p r i s e s   a   p e-
riplasmic  thiamin-binding  protein  (TbpA),  a  trans-
membrane  thiamin  channel  (ThiP),  and  an  ATPase 
responsible  for  active  transport  (ThiQ)  [39]. 
Gram-positive bacteria use another ABC  transporter 
of  operon  ykoCDEF.  This  ABC  transporter  contains 
two transmembrane components YkoC and YkoE, an 
ATPase  component  YkoD,  a n d   a   t h i a-
min/HMP-binding protein YkoF [42, 43].  
In  addition,  comparative  analysis  of  thiamin 
regulatory THI elements (ThDP riboswitches)  led  to 
the identification of YuaJ, PnuT, ThiXYZ and CytX as 
candidate thiamin-related transporters (Figure 2) [42, 
44]. It has been identified that ThiXYZ plays an role in 
the HMP salvage [45].  In  this  pathway, thiamin pro-
duced  from various organisms in basic soil is firstly 
degraded into several components including formyl 
aminopyrimidine. Secondly, formyl aminopyrimidine 
binds to the periplasmic component ThiY, and  then 
being transferred int o   t h e   c e l l .  Thirdly, YlmB mediates 
deformylation of formyl aminopyrimidine into ami-
nopyrimidine, and fourthly, TenA catalyzes the hy-
drolysis of aminopyrimidine into hydroxypyrimidine. 
Finally, ThiD catalyzes two phosphorylation steps to 
get HMP-PP. 
The distribution of thiamin biosynthetic 
pathway in pathogenic bacteria  
Landscapes  of  thiamin  biosynthetic  genes  or 
operons of some  pathogens  outlined via comparative 
genomics analysis  demonstrated  some  specific  thia-
min  biosynthetic  pathways[42].   T h e   s a l v a g e   a n d  
trans p o r t   p a t h w a y s   a r e   u b i q u i t o u s   i n   m o s t   b a c t e r i a   t o  
complement thiamin de novo biosynthesis. This might 
cripple the value of thiamin biosynthetic enzymes as 
drug  targets  since  this  enable  bacteria  to  obtain 
available exogenous thiamin. However, for those pa-
thogens lack this salvage pathways and transporters, 
s u c h   a s   M. tuberculosis, p r o m i s i n g   t a r g e t s   c a n   b e   f o u n d  
in the thiamin synthetic pathway [42]. Inhibitors can 
b e   d e s i g n e d   t o   b l o c k   t h e   b i o s y n t h e s i s   o f   t h i a m i n ,  
w h i c h   w i l l   d a m a g e   t h e   g r o w t h   a n d   s u r v i v al of bacte-
r i a .   M a n y   m e c h a n i s m s   m i g h t   b e   u s e d   f o r   i n h i b i t o r s   t o  
cross the membrane of bacteria, for example, quino-
l o n e s   p e n e t r a t e   i n t o   c e l l   t h r o u g h   O m p F   p o r i n   w h i l e  
chloramphenicol and fluoroquinolones can use Msp 
porins  of  Mycobacterium  smegmatis  [46,  47].  If  these 
pathways exert more fundamental role, such  as  the 
indispensability for Listeria monocytogenes replication, 
this might enhance its drug target value [48].  Int. J. Biol. Sci. 2011, 7 
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Figure 1. The biosynthesis of thiamin in bacteria. The thiazole moiety o f   t h i a m i n   i s   derived from an oxidative condensation 
of 1-deoxy-D-xylulose 5-phosphate (DXP) (a), cysteine (b), and glycine or tyrosine (c). When the thiazole and pyrimidine 
moieties are formed, ThiE will coupled them to be thiamin monophosphate and followed by a phosphorylation step to give 
ThDP (d). Abbreviation: Dxs, 1-deoxy-D-xylulose 5-phosphate synthase; ThiF, adenyltransferase; ThiS, sulfur carrier pro-
tein; ThiG, thiazole synthase, ThiO, glycine oxidase; ThiH, thiazole synthase; ThiI, sulfur transferase; ThiC, hydroxymethyl 
pyrimidine synthase; ThiD, hydroxymethyl pyrimidine (phosphate) kinase; NifS, sulfur dono r ;   T e n I , transcriptional regulator 
TenI; IscS, cysteine desulfurase; ThiE, thiamin phosphate synthase; ThiL, thiamin phosphate kinase. This figure is modified 
from [37]. Int. J. Biol. Sci. 2011, 7 
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Figure 2. The salvage and transport pathways of thiamin in bacteria. Enzymes involved in the salvage of thiamin and its 
precursors are shown in saffron yellow background. The transport enzymes are shown in magenta background, primary and 
ATP-dependent transporters are in circles and rectangle, respectively. Abbreviations: ThiK, thiamin kinase; ThiM, thiazole 
kinase; ThiN, thiamin pyrophosphokinase. 
Promising drug targets among thiamin 
pathway  
1-deoxy-D-xylulose 5-phosphate synthase (Dxs)  
D x s   c a t a l y s e s   t h e   f i r s t   s t e p   o f   t h i a z o l e   b i o s y n-
thesis by condensation of glyceraldehyde 3-phosphate 
and pyruvate to produce DXP (Figure  1a) [49].  This 
step also participates in the biosynthesis of pyridoxol 
(vitamin  B6)  and  isoprenoids  [50,  51].  Intriguingly, 
T h D P   i s   b o t h   t h e   p r o d u c t   o f   D x p   a n d   t h e   c o f a c t o r   o f  
Dxp.  As  the  rate-limiting  enzyme  of  the  mevalo-
nate-independent biosynthesis of isoprenoids, Dxs is 
conservative  and  ubiquitous  among  microbes,  in-
cluding pathogens. Therefore, it is an attractive drug 
target.  Additionally, the  resolved  Dxs  crystal  struc-
ture from E. coli and Deinococcus radiodurans can  fur-
ther benefit the rational design of inhibitors against it. 
Dxs contains three domains (I, II, and III), each shares 
homology with the equivalent domains of TK and the 
E1 subunit of PDH [52]. Although these enzymes cat-
alyze similar reactions and are all ThDP-dependent, 
the arrangement of the three doma i n s   o f   D x s   m o n o-
m e r   i s   d i f f e r e n t   f r o m   T K   a n d   P D H .   T h e   a c t i v e   s i t e   o f  
Dxs  is  unique,  which  is  located  at  the  interface  of 
d o m a i n s   I   a n d   I I   o f   t h e   s a m e   m o n o m e r , instead  of 
between two monomers as other examples. 
Several  inhibitors  of  Dxs  have  been  identified 
(Figure 3b). Fluoropyruvate is described as a first in-
hibitor of Dxs, which is supposed to bind covalently 
t o   t h e   a c t i v e   s i t e   o f   D x s   [13].  Dxs  from  Pseudomonas 
aeruginosa and  E.  coli were inhibited by fluoropyru-
vate  with  an  IC50 of 400 μM and 80 μM, respectively 
[53].  An o t h e r   k n o w n   i n h i b i t o r   o f   D x s   i s  
5-ketoclomazone, the metabolite of known commer-
cially  available  herbicide  clomazone  [54,  55].  The 
5-ketoclomazone  was able  to  inhibit  the  activity  of 
D x s   f r o m   Chlamydomonas w i t h   a n   I C 50 value of 0.1 mM 
[54]. However, clomazone per se h a s   n o   e f f e c t   o n   b a c-
terial growth. This suggests that plants might convert 
clomazone  into  active  pound  5-ketoclomazone, the-
reby  inhibiting  the  activity  of  Dxs[56].  Based  on  a 
known  transketolase  inhibitor,  a  target-based  ap-
proach has been used to identify possible M. tubercu-
losis  Dxs  inhibitors  [57].  A  preliminary  struc-
ture-activity  relationship  (SAR)  of  several  potential 
inhibitors against M. tuberculosis was established. So 
far,  2-methyl-3-  (4-fluorophenyl)  -5-  (4-methoxy- 
phenyl) -4H-pyrazolo[1, 5-α]pyrimidin-7-o n e   w a s   t h e  
most potent Dxs inhibitor (IC50 =10.6μM) despite its 
somewhat  toxicity  against  mammalian  cell  [57]. Ba-
cimethrin,  an  analog  of  HMP,  i s   t h e   i n h i b i t o r   o f   a  
subset  of  ThDP-dependent  enzymes  including 
α-ketoglutarate dehydrogenase, T K   a n d   D x s .   I n   b a c-
teria, bacimethrin is converted to its active metabolite 
2’-methoxy-thiamin diphosphate, which would inhi-
bit thiamin-utilizing enzymes [12].   T h e   l a s t   t hree en-
zymes of the thiamin synthetic pathway, ThiD, ThiE, 
and ThiL, a r e   a l l   c o n t r i b u t e d   t o   t h i s   c o n v e r s i o n   [12]. 
Therefore, t h e   m u t a t i o n   i n   a n y   o f   t h e   t h r e e   e n z y m e s  
might alleviate the toxicity of bacimethrin to the cell. 
It has been tested that bacimethrin could inhibit E. coli Int. J. Biol. Sci. 2011, 7 
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cell growth under a low micromolar range of mini-
mum  inhibitory  concentration (MIC). However, this 
i n h i b i t o r y   e f f e c t   c a n   b e   a b r o g a t e d   b y   l ow  levels  of 
exogenous thiamin or the HMP moity [11, 12]. 
 
F i g u r e   3 . The structure of inhibitors. Selected inhibitors of ThDP-dependent enzymes, D x s   a n d   T h i E   a r e   s h o w n   a s   a ,   b ,   a n d  
c, respectively. 
 Int. J. Biol. Sci. 2011, 7 
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Thiamin phosphate synthase (ThiE)  
ThiE catalyzes the THZ-P and HMP-PP to yield 
T h M P .   T h e   s o l v e d   T h i E   c r y s t a l   s t r u c t u r e s   o f   B. subtilis 
and  M.  tuberculosis  (http://hdl.handle.net/1813/ 
13623) have similar structure [58].   I t   i s   d i m e r   a n d   h a s  
an α/β s t r u c t u r e   w i t h   a   T I M   b a r r e l   f o l d   a n d   a   c o r e   o f  
eight  β-s t r a n d s   f l a n k e d   b y   e i g h t   α -helices.  ThiE  is  a 
crucial  synthase  for  t h i a m i n .   T h e   c e l l u l a r   t r a c e   r e-
quirement  for  thiamin  enables  it  t o   b e   s a t i s f i e d   b y  
enzymes with weak catalytic activity. The product of 
yjbQ from E. coli is a thiamin synthase homolog [59]. 
The yjbQ gene can complement the thiamin auxotro-
phy  of  E.  coli, Thermotoga,  Sulfolobus and  Pyrococcus. 
However, no structural similarity exists between YjbQ 
and  ThiE,  which  suggested  that  they  might  evolve 
from  different  origin.  ThiE  could  still  serves  as  an 
ideal  drug  target.  4-amino-2-trifluoromethyl-5- 
hydroxymethylpyrimidine (CF3-HMP) (Figure 3c) is a 
HMP analog and could inhibit the growth of E. coli. In 
the  bacteria,  CF3-H M P   i s   c o n v e r t e d   b y   T h i D   t o  
CF3-HMP pyrophosphate (CF3-HMP-PP), an analog of 
HMP-PP,  which  inhibits  the  activity  of  ThiE  [60]. 
Mounting  thiamin  level  either  endogenous  or  ex-
ogenous can reverse inhibition.  
Other potential targets among thiamin bio-
synthetic enzymes 
Among  enzymes  involved  in  thiamin  biosyn-
thesis, cysteine desulfurase (IscS) and ThiI also play a 
r o l e   i n   t h e   4 -thiouridine biosynthetic pathways dur-
ing the sulfur transfer. ThiH, ThiG, ThiF, and ThiS are 
genetically identified essential for E. coli THZ-P bio-
synthesis.  ThiO  in B.  subtilis  is  essential  for  THZ-P 
f o r m a t i o n   a n d   c a t a l y z e s   t h e   o x i d a t i o n   o f   g l y c i n e   t o  
form glycine imine [61].   T h i C   i s   t h e   o n l y   k n o w n   e n-
z y m e   t o   b e   r e q u i r e d   f o r   t h e   c o n v e r s i o n   o f   A I R   t o  
HMP-P  in  vivo,  while  ThiD  catalyzes  an  essential 
ATP-dependent  phophorylation  of  HMP-P  to  yield 
HMP-PP. Other thiamin biosynthetic enzymes whose 
crystal  structure  have been determined include ThiI 
(PDB ID: 2C5S), IscS (PDB ID: 1P3W ), ThiF (PDB ID: 
1ZUD), ThiS (PDB ID: 1ZUD, 1TYG), ThiO (PDB ID: 
1NG3), ThiG (PDB ID: 1TYG), ThiC (PDB ID: 3EPM), 
ThiD (PDB ID: 1JXI) and ThiL (PDB ID: 3C9T). These 
structures have shed light on their catalytic mechan-
isms and will contribute to the rational design of  in-
hibitors. 
Essential  enzymes  of  the  thiamin  biosynthetic 
pathway are potential antibiotic targets. Inhibitors of 
these enzymes could block the endogenous thiamin 
biosynthesis  and  lead  to  the  depletion  of  vitamin, 
thereby damaging the survival and growth of the cell. 
Transposon site hybridization (Trash) has  identified 
in  vitro  that  thiamin  biosynthetic  genes thiC, thiD, 
thiS, thiF, iscS, thiG, thiO and thiL are essential for 
M. tuberculosis [62]. Further experiments are needed to 
validate their in vivo essentiality. Inhibitors of estab-
lished  essential  gene  products  might  be  promising 
drug leads. 
The regulation of thiamin metabolism by ri-
boswitches 
Riboswitches  are  highly  conserved  metabo-
lite-sensing noncoding RNAs which are involved in 
the  regulation  of  gene  expression.  They  are  mostly 
found in the untranslated regions of mRNAs and can 
bind  to  small-molecule metabolites directly, thereby 
regulating  the  expression of metabolic-related genes 
[63-66]. Riboswitches usually act in cis form to control 
the  expression  of  their  downstream  genes, but  two 
S-adenosylmethionine (SAM) riboswitches have been 
demonstrated t o   b e   a l s o   a c t e d   i n   trans form in  addi-
tion  to  their  cis-acting  upon  the  downstream  genes 
[67]. Ty p i c a l l y   r i b o s w i t c h e s   c o n s i s t   o f   t w o   d o m a i n s , ie, 
the  aptamer  domain  and  expression  platform.  The 
highly  evolutionary  conserved  aptamer  domain  is 
used  to recognize a  target  ligand while the variable 
expression platform can alter its structure to control 
genes responsive to metabolite binding [68].  
Ri b o s w i t c h e s   c a n   s e n s e   a   v a r i e t y   o f cellular me-
tabolites whose gene products are always encoded by 
the riboswitch downstream sequence. These metabo-
lites include coenzymes, amino acids, metal ions, and 
nucleobases [69]. T h D P   r i b o s w i t c h   i s   o n e   o f   t h e   m o s t  
widespread riboswitches. Me m b e r s   o f   t h i s   c l a s s   h a v e  
been  found  in  bacteria, archaea, and eukaryotic or-
ganisms, regulating the expression of genes involved 
in the biosynthesis, salvage and transport of thiamin 
and its precursors [42, 70-75]. ThDP riboswitch also 
bears  the features of  other  riboswitch.  The  resolved 
c r y s t a l   s t r u c t u r e   o f   T h D P   r i b o s w i t c h   h e l p s   t h e   u n d e r-
standing  of  their  regulation  mechanisms.  These 
structures include thiM riboswitch from prokaryote E. 
coli and thiC riboswitch from plant Arabidopsis thaliana 
[76,  77].   T h e   h i g h   s i m i l a r i t i e s   o f   t h e   t w o   s t r u c t u r e s  
demonstrated  the  riboswitch  to  be  evolutionarily 
conserved  across  diverse  organisms.  ThDP-driven 
regulation  of  gene  expression  is  accomplished 
through  interplay  of  two  riboswitch  conformations, 
which permit the expression of thiamin biosynthetic, 
transport,  and  salvage  genes  to  be  turned  “on”  or 
“off” (Figure  4) [78]. When the intracellular concen-
tration of ThDP is relatively high, the aptamer domain 
of the riboswitch would bind to their cognate ligands 
and sensing domain adopts a stable metabolite-bound 
conformation.  According  to  organisms,  these  con-Int. J. Biol. Sci. 2011, 7 
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formations would act as transcription terminators or 
translation  inhibitors,  even  causing  mis-splicing  of 
RNA (in eukaryotes) [79]. ThDP riboswith are intrin-
sic transcription terminator and translation inhibitor. 
The  intrinsic  transcription  terminator  is  a  stable 
stem-loop structure followed by several consecutive 
uridines [80,  81].  When  encountered this terminator, 
the ternary elongation complexes of RNA polymerase 
w o u l d   b e   d i s s o c i a t e d   r a p i d l y   a n d   t h u s   l e a d   t o   a   h a l t  
transcription  [69].  Therefore,  the  concentration  of 
ThDP would determine whether to resume the tran-
scription or read through into the following thiamin 
synthetic  genes  upon  the  occupncy  of  the  aptamer 
d o m a i n   o f   r i b o s w i t c h .   R i b o s w i t c h   c a n   a l s o   h a r n e s s  
ThDP binding to form a translation inhibitor, thereby 
r e g u l a t i n g   t h e   a c c e s s   o f   m R N A   s i t e s   n e a r   A U G   s t a r t  
codons  to  the  Shine-Dalgarno  (SD)  sequence.  As  a 
result,  if  the  intracellular  concentration  of  ThDP  is 
below  the  threshold,  ThDP  would  dissociate  from 
their  riboswitch, l e a d i n g   t o   t h e   e x p r e s s i o n   o f   T h D P  
synthetic genes. 
 
Figure 4. Regulatory mechanism of ThDP riboswitches and the structure of ThDP and Pyrithiamin diphosphate. (Top) 
When ThDP is at lower concentration during the synthesis of the 5’-UTR, the ThDP riboswitch would not inhibit the 
expression of ThDP biosynthetic genes (a, b, c, left), then “gene on”. When ThDP is at higher concentration, depending on 
the the expression platform, the ThDP riboswitch would fold to a transcription terminator (a), a suppressor of translation 
initiation (b), or a modulator of splicing (c), it is the “gene off” state (a, b, c, right). (Bottom) The structure of ThDP and 
pyrithiamin diphosphate. The initiation codon and Shine-Dalgarno (SD) sequence are shaded green brown, complementary 
sequences and their alternate base pairing are shown in green. Th e   r e d   a n d   b l u e   r e p r e s e n t   T h D P   a n d   M g
2+ ions, respectively. 
This figure is modified from [76, 79]. Int. J. Biol. Sci. 2011, 7 
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Riboswitches: ideal drug targets 
It  has  been  demonstrated  that  RNA  molecules 
can  fold  into  intricate  three-dimensional structures, 
w h i c h   w i l l   f o r m   p o c k e t s   f o r   t h e   b i n d i n g   o f   s m a l l  
compounds. In this sense, the ribosome, tRNA, T box 
and  viral  RNAs  have  been  extensively  explored  as 
antibacterial or antiviral targets [82]. However, these 
a n t i m i c r o b i a l   d r u g s   m e r e l y   d e p e n d   o n   a   f o r t u i t o u s  
interaction  between  the  compound  and  its  cognate 
RNA target [83]. In contrast to above RNA, riboswitch 
r e p r e s e n t s   a   n o v e l   k i n d   o f   d r u g   t a r g e t s   d u e   t o   t h e i r  
high affinity to responsive ligand.  
ThDP riboswitch regulate  many thiamin  meta-
bolism genes in numerous bacteria, rendering  them 
promising  drug  targets  for  broad-spectrum  antibio-
tics.  Thiamin  analog  pyrithiamin  exemplifies  how 
ThDP riboswitch can act as drug target. The growth of 
many bacteria and fungi was inhibited by pyrithia-
min. Pyrithiamin c o u l d   b e   t a k e n   u p  into cell via thia-
min  transporter and further be  phosphorylated into 
pyrithiamin diphosphate by the enzyme thiamin py-
rophosphokinase.  Pyrithiamin  diphosphate  binds 
ThDP  riboswitch  at  nearly  the  identical  affinity  of 
ThDP,  which  lead  to  the  expression  of  ribos-
witch-regulated  thiamin  biosynthesis,  salvage  or 
transport  genes  be  repressed.  Because  the  limited 
endogenous  thiamin  would  soon  be  depleted,  the 
survival or growth of the cell would be prevented in a 
short  time  [84].  The  sole  difference  between  pyri-
thiamin diphosphate and ThDP is the central thiazole 
ring, in which the ThDP thiazole ring was supplanted 
by a pyridinium ring (Figure 4). Pyrithiamin-resistant 
mutants  of  B. subtilis,  E. coli,  Aspergillus oryzae  and 
Chalmydomonas  reinhardtii  bearing  mutation  in  the 
conserved domain of ThDP riboswitch, which unam-
biguously demonstrated  that  riboswitch is the  drug 
target for pyrithiamin [70, 74, 84]. Therefore, the wide 
distribution of ThDP riboswitch in several pathogens 
including the recalcitrant M. tuberculosis and promis-
cuous recognition of the central thiazole ring of ThDP 
by ThDP riboswitches  render it possible to find or 
rationally  design  ThDP  analogs  bearing  functional 
groups  other  than  those  linking  HMP  and  diphos-
phate moieties like pyrithiamin [78].  
Screening of novel riboswitch ligand analogs  as 
selective inhibitors of some metabolic pathways also 
c o n t r i b u t e   t o   t h e   e x p l o r i n g   o f   r i b o s w i t c h   a s   d r u g   t a r-
gets. Theoretically, any inhibitor of a riboswitch could 
influence gene expression, regardless of the presence 
of its ligand [85]. Thus, according to riboswitch crystal 
structures, novel compounds could be designed as a 
source of antibiotics. Indeed, the modification of pu-
rine derivatives have resulted in the screening of sev-
eral molecules that inhibit bacterial growth[86].   I t   h a s  
also  been  identified  that  a  pyrimidine  coumpound 
(PC1) binding guanine riboswitches could kill a sub-
group of bacteria [85]. More surprisingly, the fact that 
PC1 also showed some activity against the infection of 
Staphlococcus aureus i n   m o u s e   m o d e l   s u g g e s t s  it  de-
serves further research to act as an antibiotic candi-
date. These findings have established the possibility 
o f   e m p l o y i n g   t h e   r i b o s w i t c h   s t r u c t u r e s   t o   s c r e e n   n o v e l  
compounds as candidates for the development of an-
ti-microbial agents. 
 
Discussion and Conclusion  
I n   t h e   s e a r c h   f o r   n e w   d r u g   t a r g e t s   t o   c o m b a t   i n-
fection,  t h e   m o s t   d e s i r a b l e   s t r a t e g y   i s   t o   f i n d   c o m-
pounds  targeting  pathogen-specific  key  molecules. 
The thiamin biosynthetic pathway perfectly matches 
this  criterion.   T h e   D x s   a n d   T h i E   a r e   p r o p o s e d   a s 
promising enzymatic targets for novel antimicrobial 
a g e n t s .   O t h e r   e n z y m e s   o f   t h i s   p a t h w a y   c o u l d   a l s o  
serve as candidate drug targets. 
Riboswitch  have  been  extensively  studied  as 
drug targets recently [78, 87-89].   M o r e   t h a n   2 0   r ibos-
witch classes have been identified that respond to a 
spectrum of metabolites. Each riboswitch aptamer is 
featured by unique conserved primary and secondary 
structures [69]. T h D P   r i b o s w i t c h   i s   t h e   t a r g e t   o f   a n t i-
microbial  compound  pyrithiamin.  Other  ThDP  ana-
logs like pyrithiamin c o u l d   a l s o   b i n d   t o   ThDP ribos-
witch and repress the expression of bacterial thiamin 
biosynthetic enzymes. The resolved crystal structures 
of riboswitch could help the designing of their inhi-
bitors. Targeting riboswitch to develop antimicrobial 
agents  has  significant  advantages.  Despite  distantly 
evolved,  ubiquitous  riboswitches  bear  conserved 
primary  and  secondary  structures,  which  renders 
them  ideal  targets  for  broad–spectrum  antibiotics. 
Moreover,  multi-pronged  targeting  strategy  against 
multiple  riboswitches  (e.g.  there  are  thiC  and  thiO 
riboswitches in M. tuberculosis) can  dramatically  mi-
nimize the possibility of drug resistance.  
The challenge is that the trace thiamin require-
m e n t   o f   m i c r o b e s   c a n   b e   r e a d i l y   c o m p e n s a t e d   e x-
ogenously or by the activation of some other thiamin 
synthetic enzymes not yet known (for example, yjbQ). 
Therefore,  the  inhibition  can  be  easily  invalidated. 
However, for pathogens s u c h   a s  M. tuberculosis d e   n o v o  
synthesis of thiamin is indispensable due to absence 
of thiamin salvage or transporters, inhibition can  be 
more effective. Further validation of the essentiality of 
genes involved in the thiamin metabolism and regu-
latory may reveal more potential drug targets. Int. J. Biol. Sci. 2011, 7 
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